305 related articles for article (PubMed ID: 30254402)
1. Biomarkers for hepatocellular carcinoma: What's new on the horizon?
Ocker M
World J Gastroenterol; 2018 Sep; 24(35):3974-3979. PubMed ID: 30254402
[TBL] [Abstract][Full Text] [Related]
2. The predictive value of next generation sequencing for matching advanced hepatocellular carcinoma patients to targeted and immunotherapy.
Du J; Zhang E; Huang Z
Front Immunol; 2024; 15():1358306. PubMed ID: 38665910
[TBL] [Abstract][Full Text] [Related]
3. Targeted DNA and RNA sequencing of fine-needle biopsy FFPE specimens in patients with unresectable hepatocellular carcinoma treated with sorafenib.
Sakai K; Takeda H; Nishijima N; Orito E; Joko K; Uchida Y; Izumi N; Nishio K; Osaki Y
Oncotarget; 2015 Aug; 6(25):21636-44. PubMed ID: 26046304
[TBL] [Abstract][Full Text] [Related]
4. Changing role of histopathology in the diagnosis and management of hepatocellular carcinoma.
Rastogi A
World J Gastroenterol; 2018 Sep; 24(35):4000-4013. PubMed ID: 30254404
[TBL] [Abstract][Full Text] [Related]
5. Hepatocellular carcinoma: Therapeutic advances in signaling, epigenetic and immune targets.
Neureiter D; Stintzing S; Kiesslich T; Ocker M
World J Gastroenterol; 2019 Jul; 25(25):3136-3150. PubMed ID: 31333307
[TBL] [Abstract][Full Text] [Related]
6. Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?
Marisi G; Cucchetti A; Ulivi P; Canale M; Cabibbo G; Solaini L; Foschi FG; De Matteis S; Ercolani G; Valgiusti M; Frassineti GL; Scartozzi M; Casadei Gardini A
World J Gastroenterol; 2018 Sep; 24(36):4152-4163. PubMed ID: 30271080
[TBL] [Abstract][Full Text] [Related]
7. Role of liver biopsy in hepatocellular carcinoma.
Di Tommaso L; Spadaccini M; Donadon M; Personeni N; Elamin A; Aghemo A; Lleo A
World J Gastroenterol; 2019 Oct; 25(40):6041-6052. PubMed ID: 31686761
[TBL] [Abstract][Full Text] [Related]
8. Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma.
Rizzo A; Brandi G
Cancer Treat Res Commun; 2021; 27():100328. PubMed ID: 33549983
[TBL] [Abstract][Full Text] [Related]
9. Effects of liver-targeted drugs on expression of immune-related proteins in hepatocellular carcinoma cells.
Qiu MJ; He XX; Bi NR; Wang MM; Xiong ZF; Yang SL
Clin Chim Acta; 2018 Oct; 485():103-105. PubMed ID: 29940148
[TBL] [Abstract][Full Text] [Related]
10. Long non-coding RNAs in hepatocellular carcinoma: Potential roles and clinical implications.
Niu ZS; Niu XJ; Wang WH
World J Gastroenterol; 2017 Aug; 23(32):5860-5874. PubMed ID: 28932078
[TBL] [Abstract][Full Text] [Related]
11. Novel targeted therapy strategies for biliary tract cancers and hepatocellular carcinoma.
DeLeon TT; Ahn DH; Bogenberger JM; Anastasiadis PZ; Arora M; Ramanathan RK; Aqel BA; Vasmatzis G; Truty MJ; Oklu R; Bekaii-Saab TS; Borad MJ
Future Oncol; 2018 Mar; 14(6):553-566. PubMed ID: 29460642
[TBL] [Abstract][Full Text] [Related]
12. Personalized therapy in hepatocellular carcinoma: Molecular markers of prognosis and therapeutic response.
Burkhart RA; Ronnekleiv-Kelly SM; Pawlik TM
Surg Oncol; 2017 Jun; 26(2):138-145. PubMed ID: 28577719
[TBL] [Abstract][Full Text] [Related]
13. Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma.
Liu J; Liu Y; Meng L; Liu K; Ji B
Oncol Rep; 2017 Aug; 38(2):899-907. PubMed ID: 28627705
[TBL] [Abstract][Full Text] [Related]
14. Next Generation of Preclinical Liver Cancer Models.
Weber A; O'Connor T; Heikenwalder M
Clin Cancer Res; 2015 Oct; 21(19):4254-6. PubMed ID: 26169964
[TBL] [Abstract][Full Text] [Related]
15. Biomarkers for response to immunotherapy in hepatobiliary malignancies.
Lin ZF; Qin LX; Chen JH
Hepatobiliary Pancreat Dis Int; 2022 Oct; 21(5):413-419. PubMed ID: 35973935
[TBL] [Abstract][Full Text] [Related]
16. Genomic heterogeneity: next-generation sequencing enables biomarker identification for hepatocellular carcinoma.
Ziogas DE; Lykoudis EG; Roukos DH; Glantzounis GK
Biomark Med; 2017 Jul; 11(7):515-518. PubMed ID: 28699774
[No Abstract] [Full Text] [Related]
17. Comprehensive multiplatform biomarker analysis of 350 hepatocellular carcinomas identifies potential novel therapeutic options.
Ang C; Miura JT; Gamblin TC; He R; Xiu J; Millis SZ; Gatalica Z; Reddy SK; Yee NS; Abou-Alfa GK
J Surg Oncol; 2016 Jan; 113(1):55-61. PubMed ID: 26661118
[TBL] [Abstract][Full Text] [Related]
18. Circulating DNA as prognostic biomarker in patients with advanced hepatocellular carcinoma: a translational exploratory study from the SORAMIC trial.
Alunni-Fabbroni M; Rönsch K; Huber T; Cyran CC; Seidensticker M; Mayerle J; Pech M; Basu B; Verslype C; Benckert J; Malfertheiner P; Ricke J
J Transl Med; 2019 Oct; 17(1):328. PubMed ID: 31570105
[TBL] [Abstract][Full Text] [Related]
19. [Hepatocellular carcinoma: molecular pathogenesis and novel targets for therapy].
Marquardt JU; Galle PR; Teufel A
Dtsch Med Wochenschr; 2012 Apr; 137(16):855-60. PubMed ID: 22495921
[TBL] [Abstract][Full Text] [Related]
20. Advances in targeted therapies for hepatocellular carcinoma in the genomic era.
Llovet JM; Villanueva A; Lachenmayer A; Finn RS
Nat Rev Clin Oncol; 2015 Jul; 12(7):408-24. PubMed ID: 26054909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
